title: Bupropion for smokers hospitalized with acute cardiovascular disease.
abstract: OBJECTIVE
  Smoking cessation after myocardial infarction reduces cardiovascular mortality, but many smokers cannot quit despite state-of-the-art counseling intervention. Bupropion is effective for smoking cessation, but its safety and efficacy in hospitalized smokers with acute cardiovascular disease is unknown.
  
  
  METHODS
  A five-hospital randomized double-blind placebo-controlled trial assessed the safety and efficacy of 12 weeks of sustained-release bupropion (300 mg) or placebo in 248 smokers admitted for acute cardiovascular disease, primarily myocardial infarction and unstable angina. All subjects had smoking counseling in the hospital and for 12 weeks after discharge. Cotinine-validated 7-day tobacco abstinence, cardiovascular mortality, and new cardiovascular events were assessed at 3 months (end-of-treatment) and 1 year.
  
  
  RESULTS
  Validated tobacco abstinence rates in bupropion and placebo groups were 37.1% vs 26.8% (OR 1.61, 95% CI, 0.94-2.76; P=.08) at 3 months and 25.0% vs 21.3% (OR, 1.23, 95% CI, 0.68-2.23, P=.49) at 1 year. The adjusted odds ratio, after controlling for cigarettes per day, depression symptoms, prior bupropion use, hypertension, and length of stay, was 1.91 (95% CI, 1.06-3.40, P=.03) at 3 months and 1.51 (95% CI, 0.81-2.83) at 1 year. Bupropion and placebo groups did not differ in cardiovascular mortality at 1 year (0% vs 2%), in blood pressure at follow-up, or in cardiovascular events at end-of-treatment (16% vs 14%, incidence rate ratio [IRR]1.22 (95% CI: 0.64-2.33) or 1 year (26% vs 18%, IRR 1.56, 95% CI 0.91-2.69).
  
  
  CONCLUSIONS
  Bupropion improved short-term but not long-term smoking cessation rates over intensive counseling and appeared to be safe in hospitalized smokers with acute cardiovascular disease.
authors.affiliation: Tobacco Research and Treatment Center, General Medicine Division, and Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA. nrigotti@partners.org
authors.forename: Nancy A
authors.initials: NA
authors.lastname: Rigotti
authors.forename: Anne N
authors.initials: AN
authors.lastname: Thorndike
authors.forename: Susan
authors.initials: S
authors.lastname: Regan
authors.forename: Kathleen
authors.initials: K
authors.lastname: McKool
authors.forename: Richard C
authors.initials: RC
authors.lastname: Pasternak
authors.forename: Yuchiao
authors.initials: Y
authors.lastname: Chang
authors.forename: Susan
authors.initials: S
authors.lastname: Swartz
authors.forename: Nancy
authors.initials: N
authors.lastname: Torres-Finnerty
authors.forename: Karen M
authors.initials: KM
authors.lastname: Emmons
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Singer
mesh_terms: D000208:Acute Disease; D000789:Angina, Unstable / Q000150:complications*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications*; D012907:Smoking / Q000188:drug therapy*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion